GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, …
GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16...
FDA Approves Merck's HPV Vaccine, GARDASIL®9, to Prevent …
Dec 11, 2014 · GARDASIL 9 includes the greatest number of HPV types in any available HPV vaccine Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA)
GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, …
GARDASIL 9 helps protect individuals ages 9 to 45 against the following diseases caused by 9 types of HPV: cervical, vaginal, and vulvar cancers in females, anal cancer, certain head and neck cancers, such as throat and back of mouth cancers and genital warts in both males and females.
FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain …
Jun 12, 2020 · GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Now Approved for the Prevention of HPV-Related Cervical, Vaginal, Vulvar, Anal, Oropharyngeal and Other Head and Neck Cancers.
Merck Issues Statement on GARDASIL® Litigation
RAHWAY, N.J., Jan. 28, 2025 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today reaffirmed its commitment to defending the safety and efficacy of its HPV vaccines. Merck is a defendant in product liability lawsuits in the United States involving GARDASIL® (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and […]
Gardasil | FDA - U.S. Food and Drug Administration
Tradename: Gardasil Manufacturer: Merck & Co., Inc. Indications: Prevention of vulvar and vaginal cancer
GARDASIL 9 | FDA - U.S. Food and Drug Administration
Mar 15, 2024 · Product approval information for Human Papillomavirus 9-valent Vaccine, Recombinant also known as Gardasil 9.
GARDASIL® is a vaccine indicated in girls and women 9 through26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine:
Merck shares plunge as company pauses Gardasil vaccine …
The low end of Merck's revenue guidance assumes no further shipments in China, and less than $1 billion in sales at the high end. Merck CEO Robert Davis said on an earnings call that Gardasil ...
Efficacy of GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.